PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
20.86%
Revenue growth exceeding 1.5x Healthcare median of 2.70%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
30.04%
Gross profit growth exceeding 1.5x Healthcare median of 0.14%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
-72.06%
Negative EBIT growth while Healthcare median is 3.90%. Seth Klarman would check if external or internal factors caused the decline.
-130.61%
Negative operating income growth while Healthcare median is 3.90%. Seth Klarman would check if structural or cyclical issues are at play.
-61.23%
Negative net income growth while Healthcare median is 4.21%. Seth Klarman would investigate factors dragging net income down.
100.00%
EPS growth exceeding 1.5x Healthcare median of 3.59%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
100.00%
Diluted EPS growth exceeding 1.5x Healthcare median of 3.59%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
-100.00%
Share reduction while Healthcare median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
-100.00%
Diluted share reduction while Healthcare median is 0.12%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
-122.31%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-232.20%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
-100.00%
Negative 10Y revenue/share CAGR while Healthcare median is 57.93%. Seth Klarman would see if the entire sector or just this company faces long-term decline.
-100.00%
Negative 5Y CAGR while Healthcare median is 41.85%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-100.00%
Negative 3Y CAGR while Healthcare median is 24.56%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
100.00%
OCF/share CAGR exceeding 1.5x Healthcare median of 25.03% over 10 years. Joel Greenblatt would verify if a unique competitive moat underlies these cash flows.
100.00%
5Y OCF/share growth exceeding 1.5x Healthcare median of 62.91%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
100.00%
3Y OCF/share growth > 1.5x Healthcare median of 21.96%. Joel Greenblatt might see a recent competitive advantage translating into cash improvements.
100.00%
Net income/share CAGR 75-90% of Healthcare median. John Neff would push for cost or revenue enhancements to match peers.
100.00%
5Y net income/share CAGR > 1.5x Healthcare median of 24.59%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
100.00%
3Y net income/share CAGR of 100.00% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
-100.00%
Negative 10Y equity/share growth while Healthcare median is 155.82%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-100.00%
Negative 5Y equity/share growth while Healthcare median is 60.63%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-100.00%
Negative 3Y equity/share growth while Healthcare median is 11.30%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.53%
AR growth of 17.53% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
2.84%
Inventory growth of 2.84% while Healthcare median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
-39.05%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-100.00%
Negative BV/share change while Healthcare median is 3.14%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-4.41%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-60.00%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
12.05%
Our SG&A slightly up while Healthcare is cutting. Peter Lynch wonders if we overspend or if the median underinvests in marketing.